These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32385907)

  • 1. Structural Consequences of the 1,2,3-Triazole as an Amide Bioisostere in Analogues of the Cystic Fibrosis Drugs VX-809 and VX-770.
    Doiron JE; Le CA; Bacsa J; Breton GW; Martin KL; Aller SG; Turlington M
    ChemMedChem; 2020 Sep; 15(18):1720-1730. PubMed ID: 32385907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809.
    Doiron JE; Le CA; Ody BK; Brace JB; Post SJ; Thacker NL; Hill HM; Breton GW; Mulder MJ; Chang S; Bridges TM; Tang L; Wang W; Rowe SM; Aller SG; Turlington M
    Chemistry; 2019 Mar; 25(14):3662-3674. PubMed ID: 30650214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells.
    Ruffin M; Roussel L; Maillé É; Rousseau S; Brochiero E
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L635-L641. PubMed ID: 29351441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis.
    Baldelli S; Fusi M; Cozzi V; Clementi E; Faelli NML; Russo M; Colombo C; Cattaneo D
    Clin Chem Lab Med; 2019 Oct; 57(11):e274-e278. PubMed ID: 31141479
    [No Abstract]   [Full Text] [Related]  

  • 5. Radical new treatments for cystic fibrosis.
    Arch Dis Child; 2015 Aug; 100(8):727. PubMed ID: 26078470
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating Specific Variants Causing Cystic Fibrosis.
    Cutting GR
    JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
    [No Abstract]   [Full Text] [Related]  

  • 7. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
    Connett GJ
    Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis drug is not cost effective, says NICE.
    Gulland A
    BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
    [No Abstract]   [Full Text] [Related]  

  • 10. [Causal therapy is available].
    Meißner T
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
    [No Abstract]   [Full Text] [Related]  

  • 11. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
    Elborn JS; Ramsey B; Wainwright C; Boyle M
    Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
    [No Abstract]   [Full Text] [Related]  

  • 13. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 14. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
    Kopeikin Z; Yuksek Z; Yang HY; Bompadre SG
    J Cyst Fibros; 2014 Sep; 13(5):508-14. PubMed ID: 24796242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
    Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
    Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
    [No Abstract]   [Full Text] [Related]  

  • 19. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
    Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
    [No Abstract]   [Full Text] [Related]  

  • 20. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.